Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort

Journal of Infectious Diseases

Volumn 211, Issue 4, 2015, Pages 590-599

  Corbett, Kizzmekia S ^a   Katzelnick, Leah ^a,b   Tissera, Hasitha ^c   Amerasinghe, Ananda ^c   De Silva, Aruna Dharshan ^d   De Silva, Aravinda M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Department of Prevention   (United Kingdom)

^d Genetech Research Institute   (Sri Lanka)

Author keywords

dengue fever; dengue virus; inapparent dengue; neutralizing antibody; Sri Lanka

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DENGUE; DENGUE VIRUS; DRIED BLOOD SPOT TESTING; FEVER; FLOW CYTOMETRY; HUMAN; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; PROGNOSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REINFECTION; SEROTYPE; SRI LANKAN; BLOOD; CLASSIFICATION; FEMALE; IMMUNOLOGY; INFANT; MALE; PRESCHOOL CHILD; PROSPECTIVE STUDY; RECURRENT DISEASE; SRI LANKA;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VIRUS; FEMALE; HUMANS; INFANT; MALE; PROSPECTIVE STUDIES; RECURRENCE; SEROEPIDEMIOLOGIC STUDIES; SRI LANKA;

EID: 84922456237     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu481     Document Type: Article

References (40)

1. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004; 10:S98-109.
2. Guzman A, Isturiz RE. Update on the global spread of dengue. Int J Antimicrob Agents 2010; 36 (suppl 1):S40-2.
3. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496:504-7.
4. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988; 38:172-80.
5. Sangkawibha N, Rojanasuphot S, Ahandrik S, et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 1984; 120:653-69.
6. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990; 42:179-84.
7. Guzman MG, Kouri G, Valdes L, et al. Epidemiologic studies on Dengue in Santiago de Cuba, 1997. Am J Epidemiol 2000; 152:793-9; discussion 804.
8. Guzman MG, Alvarez A, Vazquez S, et al. Epidemiological studies on dengue virus type 3 in Playa municipality, Havana, Cuba, 2001-2002. Int J Infect Dis 2012; 16:e198-203.
9. Halstead SB. Observations related to pathogensis of dengue hemorrhag-ic fever. VI. Hypotheses and discussion. Yale J Biol Med 1970; 42:350-62.
10. Guzman M, Alvarez M, Halstead S. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 2013; 158:1445-59.
11. Flipse J, Wilschut J, Smit JM. Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans. Traffic 2013; 14:25-35.
12. Teerasut C, Lei HY, Natthakorn K, et al. The serotype-independent but concentration-dependent enhancing antibodies among Thai dengue patients. Southeast Asian J Trop Med Public Health 2012; 43:624-33.
13. Halstead SB, Porterfield JS, O'Rourke EJ. Enhancement of Dengue Virus Infection in Monocytes by Flavivirus Antisera. Am J Trop Med Hyg 1980; 29:638-42.
14. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40:444-51.
15. Balsitis SJ, Williams KL, Lachica R, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 2010; 6:e1000790.
16. Endy TP, Nisalak A, Chunsuttitwat S, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004; 189:990-1000.
17. Olkowski S, Forshey BM, Morrison AC, et al. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis 2013; 208:1026-33.
18. Puschnik A, Lau L, Cromwell EA, Balmaseda A, Zompi S, Harris E. Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans. PLoS Negl Trop Dis 2013; 7:e2274.
19. OhAinle M, Balmaseda A, Macalalad AR, et al. Dynamics of dengue disease severity determined by the interplay between viral genetics and se-rotype-specific immunity. Sci Transl Med 2011; 3:114ra28.
20. Tissera H, Amarasinghe A, De Silva AD, et al. Burden of dengue infection and disease in a pediatric cohort in urban Sri Lanka. Am J Trop Med Hyg 2014; 91:132-7.
21. Tissera H, Amarasinge A, de Silva AM, et al. Surveillance of dengue in a community cohort in metropolitan Colombo, Sri Lanka: part I methods and study population. WHO Dengue Bull 2013; 37:141-54.
22. Snijdewind IJ, van Kampen JJ, Fraaij PL, van der Ende ME, Osterhaus ADGruters RA. Current and future applications of dried blood spots in viral disease management. Antiviral Res 2012; 93:309-21.
23. Balmaseda A, Saborio S, Tellez Y, et al. Evaluation of immunologi-cal markers in serum, filter-paper blood spots, and saliva for dengue diagnosis and epidemiological studies. J Clin Virol 2008; 43: 287-91.
24. Wahala WMPB, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 2009; 392:103-13.
25. Kanakaratne N, Wahala WM, Messer WB, et al. Severe dengue epidemics in Sri Lanka, 2003-2006. Emerg Infect Dis 2009; 15:192-9.
26. Messer WB, Vitarana UT, Sivananthan K, et al. Epidemiology of dengue in Sri Lanka before and after the emergence of epidemic dengue hem-orrhagic fever. Am J of Trop Med Hyg 2002; 66:765-73.
27. Kraus AA, Messer W, Haymore LB, de Silva AM. Comparison of plaque-and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol 2007; 45:3777-80.
28. de Alwis R, de Silva A. Measuring antibody neutralization of dengue virus (DENV) using a flow cytometry-based technique. In: Padmanab-han R, Vasudevan SG, eds. Dengue. Vol 1138. New York: Springer, 2014:27-39.
29. Prince HE, Matud JL. Estimation of dengue virus IgM persistence using regression analysis. Clin Vaccine Immunol 2011; 18:2183-5.
30. Endy TP, Anderson KB, Nisalak A, et al. Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. PLoS Negl Trop Dis 2011; 5:e975.
31. Popper SJ, Gordon A, Liu M, Balmaseda A, Harris E, Relman DA. Temporal dynamics of the transcriptional response to dengue virus infection in Nicaraguan children. PLoS Negl Trop Dis 2012; 6:e1966.
32. Cobra C, Rigau-Pérez JG, Kuno G, Vomdam V. Symptoms of dengue fever in relation to host immunologic response and virus serotype, Puerto Rico, 1990-1991. Am J Epidemiol 1995; 142:1204-11.
33. Leitmeyer KC, Vaughn DW, Watts DM, et al. Dengue virus structural differences that correlate with pathogenesis. J Virol 1999; 73:4738-47.
34. Lai C-Y, Williams KL, Wu Y-C, et al. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis 2013; 7:e2451.
35. Lai C-Y, Tsai W-Y, Lin S-R, et al. Antibodies to Envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 2008; 82:6631-43.
36. Hu D, Li J, Wang D, et al. Analysis of serum neutralizing antibody response in patients with primary dengue virus type 1 infection. Nan Fang Yi Ke Da Xue Xue Bao 2012; 32:1773-6, 91.
37. Montoya M, Gresh L, Mercado JC, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis 2013; 7: e2357.
38. Reich NG, Shrestha S, King AA, et al. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc Interface 2013; 10.
39. Gubler DJ. Dengue/dengue haemorrhagic fever: history and current status. Novartis Found Symp 2006; 277:3-16; discussion 16-22, 71-3, 251-3.
40. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559-67.